Aim To review the effectiveness and safety of switching from an originator anti-TNF
(Remicade®) to a biosimilar (CT-P13) in patients with inflammatory bowel disease (IBD) …

Background & Aims There is evidence that it is safe and effective for patients with
inflammatory bowel diseases (IBD) to switch from maintenance therapy with an original …

Background Patients suffering from inflammatory bowel diseases (IBD) and treated with
originator infliximab are increasingly being switched to biosimilars. Some patients, however …

Background: Biological therapy has revolutionized the treatment of inflammatory bowel
disease (IBD). After the expiration of patents for biological innovator products, development …

Background: As the patents of originator biologics are expiring, biosimilar versions are
becoming available for the treatment of inflammatory bowel disease (IBD). However …

Background and aim The biosimilar of infliximab (CT-P13) has been approved for the same
indications held by the infliximab reference product (Remicade®); however, there are few …

Background Inflammatory bowel disease is treated with anti-TNF agents such as infliximab
and its biosimilars, but use of biosimilars is limited due to perceived risks of adverse events …

Objective Project NORTH compared real-world clinical and economic outcomes in Swedish
patients with inflammatory bowel disease (IBD) who switched from originator infliximab to its …

Background: Biosimilar infliximab (IFX) seems to have similar efficacy and safety to original
preparation in patients with inflammatory bowel diseases (IBD) who are naïve to anti-TNFa …

Background Though a single nonmedical switch from the originator infliximab (IFX) to a
biosimilar is considered effective and safe for most patients with inflammatory bowel disease …